俄羅斯藥品市場 是由出版商RNCOS E-Services Pvt. Ltd.在2008年09月所出版的。
這份英文市場調查報告書包含115 Pages 價格從美金550起跳。
Abstract
According to “Russian Pharma Sector Analysis”, the Russian
pharmaceutical market grew at a slow pace in 2007 but it still is attractive
as compared to previous years that recorded no-so-impressive performance due
to the state segment. In the Russian pharma market, both the retail segment
and parapharmaceutical market registered double-digit growth in sales value,
with parapharmaceutical recording the highest growth rate and retail segment
contributing the maximum share in sales value terms.
This research report provides an extensive research and objective analysis on
the growing demand of pharmaceuticals in Russia and presents a clear picture
of the country' s healthcare and pharmaceutical market. It covers Russian
demographics, structure of healthcare sector, size and growth of
pharmaceutical market, leading drugs, segment-wise break up, and information
on major therapy areas to give strategic insight into the market. This report
briefly discusses the major players operating in each segment of the market.
The share of imported and domestic drugs, RX and OTC drugs, and sales
structure by ATC group has also been analyzed in context of the Russian
pharmaceutical market.
Key Research Findings
- The Russian pharmaceutical market grew 16% in 2007 as compared to 2006.
- State segment grew at a slower rate while the parapharmaceutical and
commercial segments recorded impressive growth rates in 2007.
- In 2007, new drugs segment increased at fast pace as more than 230 new
drug trade names appeared in the Russian pharmaceutical market.
- In 2007, Sanofi-Aventis was the leader of the retail sales among the drug
manufacturers in commercial drug market segment.
- The consumption value provided by the State Reimbursement Program (DLO)
decreased in 2007 due to diminishing requirement.
- The Russian pharmaceutical market is forecasted to grow at a CAGR of
14.36% by 2012.
Key Issues Analyzed in the Report
- Where does the Russian pharmaceutical market stand in comparison to other
key global markets?
- What is the market size of various segments in the Russian pharmaceutical
industry?
- What is the proportion of domestic and imported drugs in each segment?
- What are the opportunities that will emerge in future for the market?
- Who are the major players in the Russian pharmaceutical market?
Research Methodology Used in the Report
Information Sources
The information in this report has been taken from various credible sources
like books, newspapers, trade journals, white papers, industry portals,
government agencies, trade associations, monitoring industry news and
developments, and through access to more than 3000 paid databases.
Analysis Methods
The analysis methods used in this report include ratio analysis, historical
trend analysis, linear regression analysis using software tools, judgmental
forecasting, and cause and effect analysis.
For the purpose of this report, the Russian pharmaceutical market has been considered to consist of the following segments:
- Commercial drugs market;
- State segment (DLO programme and Hospital Segment)
- Parapharmaceutical segment (Food Supplements and Cosmetics)
Table of Contents
1. Analyst View
2. Global Pharmaceutical Market
- 2.1 Geographical Performance
- 2.2 Leading Therapy Classes
- 2.3 Leading Companies
- 2.4 Leading Drugs
3. Russia - Demographics & Healthcare Profile
- 3.1 Life Expectancy
- 3.2 Age Breakup
- 3.3 Hospital Beds & Doctors
- 3.4 Healthcare Expenditure
4. Pharmaceutical Market
- 4.1 Market Size & Growth
- 4.2 Comparative Analysis
- 4.3 Commercial Drugs Market
- 4.3.1 Trends
- 4.3.2 Imported & Domestic Drugs
- 4.3.3 RX & OTC Drugs
- 4.3.4 Sales Structure - By ATC Groups
- 4.3.5 Leading Companies
- 4.3.6 Leading Drugs
- 4.3.7 Price Analysis
- 4.4 State Segment
- 4.4.1 DLO Reimbursement Programme
- 4.4.1.1 Imported & Domestic Drugs
- 4.4.1.2 RX & OTC Drugs
- 4.4.1.3 Sales Structure - By ATC Groups
- 4.4.1.4 Leading Companies
- 4.4.1.5 Leading Drugs
- 4.4.2 Hospital Segment
- 4.4.2.1 Imported & Domestic Drugs
- 4.4.2.2 Leading Companies
- 4.4.2.3 Leading Drugs
- 4.4.2.4 Drugs Demand - By Price
- 4.5 Parapharmaceutical Market
- 4.5.1 Nutritional Supplements Market
- 4.5.1.1 Imported & Domestic Supplements
- 4.5.1.2 Leading Supplements
- 4.5.1.3 Supplement Demand - By Price
- 4.6 New Drugs
5. Industry Analysis
- 5.1 Market Driving Forces
- 5.1.1 Aging Population
- 5.1.2 Increasing Volume & Sales of Expensive Drugs
- 5.1.3 Government Support & Funding
- 5.1.4 Medical Insurance
- 5.1.5 Growing Disposable Income
- 5.2 Growth Avenues
- 5.2.1 Cardiovascular Drugs
- 5.2.2 HIV Drugs
- 5.2.3 High Insulin Demand
- 5.2.4 Cancer Drugs
- 5.2.5 Foreign Players
- 5.2.6 Generics
- 5.2.7 Clinical Trials Market
- 5.3 Market Roadblocks
- 5.3.1 Declining Population
- 5.3.2 Low Growth in Spending under DLO Programme
- 5.3.3 Price Control
- 5.3.4 Drug Counterfeiting & Weak IPR Regime
6. Future Outlook (2008-2012)
- 6.1 Commercial Drugs Market
- 6.2 State Segment
- 6.3 Parapharmaceutical Market
7. Key Players
- 7.1 Sanofi-Aventis
- 7.2 Novartis International AG
- 7.3 Roche Group
- 7.4 Pfizer Inc
- 7.5 AstraZeneca Plc
List of Figures:
- Figure 2-1: Global - Pharmaceutical Market (in Billion US$), 2002-2007
- Figure 2-2: Global - Growth of Pharmaceutical Market (%), 2002-2007
- Figure 2-3: Global - Pharmaceutical Market* by Region (%), 2007
- Figure 2-4: Global - Top Five Pharmaceutical Companies by Sales & Net
Income (in Billion US$), 2007
- Figure 3-1: Russia - Population (in Million), 2002-2007
- Figure 3-2: Russia - Life Expectancy of Male & Female (in Years),
2002-2008E
- Figure 3-3: Russia - Population Breakup by Age (%), 2002-2008E
- Figure 3-4: Russia - Number of Doctors (per ' 000 Population), 2002-2007E
- Figure 3-5: Russia - Number of Hospital Beds (per ' 000 Population),
2002-2007E
- Figure 3-6: Russia - Share of Healthcare Expenditure in GDP (%), 2002-2007E
- Figure 3-7: Russia - Per Capita Healthcare Expenditure (in US$), 2002-2007E
- Figure 4-1: Russia - Pharmaceutical Market (in Million US$), 2006 & 2007
- Figure 4-2: Russia - Share of Key Segments in Pharmaceutical Market (%),
2006 & 2007
- Figure 4-3: Global - Top Pharmaceutical Retail Markets (in Billion US$),
2007
- Figure 4-4: Global - Growth of Top Pharmaceutical Retail Markets (%), 2007
- Figure 4-5: Global - Per Capita Drug Consumption in Top Pharmaceutical
Markets (in US$), 2006
- Figure 4-6: Russia - Share of Personal & State Financing in Pharmaceutical
Market (%), 2004-2006
- Figure 4-7: Global - Share of Personal & State Financing in Top
Pharmaceutical Markets (%), 2006
- Figure 4-8: Russia - Commercial Drugs Market (in Million US$), 2006 & 2007
- Figure 4-9: Russia - Trends in Commercial Drugs Market (%), 2007
- Figure 4-10: Russia - Share of Imported & Domestic Drugs in Commercial
Drugs Market by Sales Value (%), 2006 & 2007
- Figure 4-11: Russia - Share of Imported & Domestic Drugs in Commercial
Drugs Market by Sales Volume (%), 2006 & 2007
- Figure 4-12: Russia - Share of RX & OTC Drugs in Commercial Drugs Market
by Sales Value (%), 2006 & 2007
- Figure 4-13: Russia - Share of RX & OTC Drugs in Commercial Drugs Market
by Sales Volume (%), 2006 & 2007
- Figure 4-14: Russia - Growth* of Major ATC Groups in Commercial Drugs
Market (%), 2007
- Figure 4-15: Russia - Price Index for Drugs in Commercial Drugs Market
(%), 2005-2007
- Figure 4-16: Russia - Price Index for Imported & Domestic Drugs in
Commercial Drugs Market (%), 2005-2007
- Figure 4-17: Russia - Consumer Price Index (%), 2007
- Figure 4-18: Russia - State Segment of Pharmaceutical Market (in Million
US$), 2006 & 2007
- Figure 4-19: Russia - Consumption under DLO Programme (in Billion US$),
2006* & 2007
- Figure 4-20: Russia - Share of Imported & Domestic Drugs in the DLO List
of Full & Trade Name (%), 2007
- Figure 4-21: Russia - Share of Imported & Domestic Drugs under DLO
Programme by Sales Value (%), 2006 & 2007
- Figure 4-22: Russia - Share of RX & OTC Drugs under DLO Programme by Sales
Value (%), 2006 & 2007
- Figure 4-23: Russia - Share of RX & OTC Drugs under DLO Programme by Sales
Volume (%), 2006 & 2007
- Figure 4-24: Russia - Share of ATC Groups under DLO Programme by Sales
Value (%), 2006 & 2007
- Figure 4-25: Russia - Share of Imported & Domestic Drugs under Hospital
Segment by Sales Value (%), 2006 & 2007
- Figure 4-26: Russia - Share of Imported & Domestic Drugs under Hospital
Segment by Sales Volume (%), 2006 & 2007
- Figure 4-27: Russia - Drugs Demand by Price under Hospital Segment (%),
2007
- Figure 4-28: Russia - Parapharmaceutical Market (in Million US$), 2006 &
2007
- Figure 4-29: Russia - Nutritional Supplements Market (in Million US$),
2005 & 2006
- Figure 4-30: Russia - Nutritional Supplements Market (in Million Units),
2005 & 2006
- Figure 4-31: Russia - Share of Imported & Domestic Nutritional Supplements
Sales* (%), 2006
- Figure 4-32: Russia - Breakup* of Imported Nutritional Supplements by
Country (%), 2006
- Figure 4-33: Russia - Imported & Domestic Nutritional Supplements Demand
by Price (%), 2006
- Figure 4-34: Russia - Sales Structure of New Drugs by Value & Volume (%),
2007
- Figure 5-1: Russia - Population aged 65 Years & Above (in Million),
2001-2007
- Figure 5-2: Russia - Commercial Drugs Demand by Price (%), 2006 & 2007
- Figure 5-3: Russia - Structure of Pharmaceutical Market Growth (%), 2007
- Figure 5-4: Russia - Pharmaceutical Market Growth* by Segment (%), 2007
- Figure 5-5: Russia - Personal Disposable Income (in Billion US$),
2002-2007E
- Figure 5-6: Russia - Share of Deaths from Cardiovascular Diseases in Total
Deaths (%), 2005 & 2030F
- Figure 5-7: Russia - Number of HIV Patients (in Million), 2003 & 2020F
- Figure 5-8: Russia - Anti-HIV Drugs Import (in Million US$), 2004 & 2005
- Figure 5-9: Russia - Forecast for Number of Diagnosed Diabetes Patients*
(in ' 000), 2003 & 2025F
- Figure 5-10: Russia - Insulin Market (in Million US$), 2006E-2008F
- Figure 5-11: Russia - Share of Deaths from Cancer in Total Deaths (%),
2005 & 2030F
- Figure 5-12: Russia - Generic Drugs Market (in Billion Euro), 2006 & 2010F
- Figure 5-13: Russia - Number of Approved Clinical Trials (2001-2006)
- Figure 5-14: Russia - Number of Patients Participating in Clinical Trials
(2002 & 2006)
- Figure 5-15: Russia - Clinical Trials by Therapeutic Areas (%), 2007
- Figure 5-16: Russia - Clinical Trials by Sponsor Country (%), 2007
- Figure 5-17: Russia - Forecast for Population (in Million), 2008-2012
- Figure 6-1: Russia - Forecast for Pharmaceutical Market (in Million US$),
2008-2012
- Figure 6-2: Russia - Forecast for Pharmaceutical Market by Segments (%),
2012
- Figure 6-3: Russia- Forecast for Population aged 65 Years & Above (in
Million) 2008-2012
- Figure 6-4: Russia - Forecast for Commercial Drugs Segment (in Million
US$), 2008-2012
- Figure 6-5: Russia - Forecast for State Segment (in Million US$), 2008-2012
- Figure 6-6: Russia - Forecast for DLO Market (in Billion US$), 2008-2012
- Figure 6-7: Russia - Forecast for Personal Disposable Income (in Billion
US$), 2008-2012
- Figure 6-8: Russia - Forecast for Parapharmaceutical Market (in Million
US$), 2008-2012
List of Tables:
- Table 2-1: Global - Pharmaceutical Market by Region (in Billion US$), 2007
- Table 2-2: Global - Leading Therapy Classes by Sales (in Billion US$), 2007
- Table 2-3: Global - Leading Drugs by Sales (in Billion US$), 2007
- Table 4-1: Russia - Leading Pharmaceutical Companies by Sales (in Million
US$), 2006 & 2007
- Table 4-2: Russia - Sales Structure of ATC Groups in Commercial Drugs
Market, 2007
- Table 4-3: Russia - Leading Pharmaceutical Companies in Commercial Drugs
Market by Sales (in Million US$), 2006 & 2007
- Table 4-4: Russia - Leading Drugs in Commercial Drugs Market by Sales (in
Million US$), 2006 & 2007
- Table 4-5: Russia - Sales Structure of ATC Groups under DLO Programme, 2007
- Table 4-6: Russia - Leading Pharmaceutical Companies under DLO Programme
(in Million US$), 2006 & 2007
- Table 4-7: Russia - Leading Drugs under DLO Programme by Sales (in Million
US$), 2006 & 2007
- Table 4-8: Russia - Leading Pharmaceutical Companies under Hospital
Segment (%), 2007
- Table 4-9: Russia - Leading Drugs under Hospital Segment by Sales (in
Million US$), 2007
- Table 4-10: Russia - Leading Nutritional Supplements by Sales (in Million
US$), 2005 & 2006
- Table 4-11: Russia - Top 20 New Trade Names on Commercial Market (in ' 000
US$), 2007
- Table 7-1: Sanofi-Aventis - Key Financials (in Million Euro), 2005-2007
- Table 7-2: Novartis International AG - Key Financials (in Million US$),
2005-2007
- Table 7-3: Roche Group - Key Financials (in Million CHF), 2005-2007
- Table 7-4: Pfizer Inc - Key Financials (in Million US$), 2005-2007
- Table 7-5: AstraZeneca Plc - Key Financials (in Million US$), 2005-2007
|
